Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

Daniel D. Mikol, Bernard M.J. Uitdehaag, Patricia K. Coyle et al.|The Lancet Neurology|2008

Cited by 484